Kenta Biotech Reports Phase IIa Data with Lead Candidate Panobacumab in Hospital-Acquired Pneumonia

BERNE, Switzerland--(BUSINESS WIRE)--Kenta Biotech has presented positive Phase IIa results of its lead drug candidate, panobacumab (KBPA101), showing it is safe and well tolerated in patients with hospital-acquired pneumonia caused by Pseudomonas aeruginosa. The compound, a fully human IgM monoclonal antibody, has the potential to reduce mortality rates. The Phase IIa data were presented yesterday in a poster session at the 49th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.